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YoBACKGROUND Lipoprotein(a) [Lp(a)], a major carrier of oxidized phospholipids (OxPL), is associated with an increased
incidence of aortic stenosis (AS). However, it remains unclear whether elevated Lp(a) and OxPL drive disease progression
and are therefore targets for therapeutic intervention.
OBJECTIVES This study investigated whether Lp(a) and OxPL on apolipoprotein B-100 (OxPL-apoB) levels are
associated with disease activity, disease progression, and clinical events in AS patients, along with the mechanisms
underlying any associations.
METHODS This study combined 2 prospective cohorts and measured Lp(a) and OxPL-apoB levels in patients with AS
(Vmax >2.0 m/s), who underwent baseline 18F-sodium ﬂuoride (18F-NaF) positron emission tomography (PET), repeat
computed tomography calcium scoring, and repeat echocardiography. In vitro studies investigated the effects of Lp(a)
and OxPL on valvular interstitial cells.
RESULTS Overall, 145 patients were studied (68% men; age 70.3  9.9 years). On baseline positron emission
tomography, patients in the top Lp(a) tertile had increased valve calciﬁcation activity compared with those in lower tertiles
(n ¼ 79; 18F-NaF tissue-to-background ratio of the most diseased segment: 2.16 vs. 1.97; p ¼ 0.043). During follow-up,
patients in the top Lp(a) tertile had increased progression of valvular computed tomography calcium score (n ¼ 51; 309
AU/year [interquartile range: 142 to 483 AU/year] vs. 93 AU/year [interquartile range: 56 to 296 AU/year; p¼ 0.015), faster
hemodynamic progression on echocardiography (n¼ 129; 0.23  0.20 m/s/year vs. 0.14  0.20 m/s/year] p ¼ 0.019), and
increased risk for aortic valve replacement and death (n ¼ 145; hazard ratio: 1.87; 95% CI: 1.13 to 3.08; p ¼ 0.014),
compared with lower tertiles. Similar results were noted with OxPL-apoB. In vitro, Lp(a) induced osteogenic differentiation
of valvular interstitial cells, mediated by OxPL and inhibited with the E06 monoclonal antibody against OxPL.
CONCLUSIONS In patients with AS, Lp(a) and OxPL drive valve calciﬁcation and disease progression. These ﬁndings
suggest lowering Lp(a) or inactivating OxPL may slow AS progression and provide a rationale for clinical trials to test thishypothesis. (J Am Coll Cardiol 2019;73:2150–62) © 2019 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2019.01.070
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2151AB BR E V I A T I O N S
AND ACRONYM S
18F-NaF = ﬂuorine-18 sodium
ﬂuoride
apoB = apolipoprotein B-100
AS = aortic valve stenosis
AVR = aortic valve
replacement
CT = computed tomography
Lp(a) = lipoprotein(a)
OxPL = oxidized phospholipids
PET = positron emission
tomography
TBR = tissue-to-background
ratio
VIC = valvular interstitial cellA ortic valve stenosis (AS) is the commonestform of valvular heart disease in developedcountries, and its disease burden is antici-
pated to double over the next 50 years (1). Following
the failure of statins in reducing AS progression (2),
effective medical therapies are lacking. The only treat-
ment option is surgical or transcatheter aortic valve
replacement (AVR), after patients develop severe ste-
nosis and symptoms (3). Patients with AS are elderly,
often have multiple comorbidities and are not well
suited to major surgery or intervention. Moreover,
these procedures are expensive and are associated
with perioperative as well as long-term morbidity
and mortality. There is, therefore, an unmet clinical
need for novel therapies to slow AS progression,
thereby obviating the requirement for AVR altogether.SEE PAGE 2163Lipoprotein(a) (Lp[a]) is a major carrier of
oxidized phospholipids (OxPL) (4,5) and has been
established as a causal risk factor for AS in several
genetic and population studies (6–8). Lp(a) is unaf-
fected by statin therapy, but levels can now be
reduced with novel compounds (9), making Lp(a) a
potential therapeutic target in AS. The risk factors
associated with incident AS may differ from those
associated with disease progression, due to patho-
physiological differences in the initiation and prop-
agation phases of the disease (10). Before Lp(a) or its
associated OxPL can be considered viable targets for
therapeutic intervention in AS, prospective longitu-
dinal studies are required to establish whether Lp(a)
and OxPL are associated with disease progression—in
addition to mechanistic work investigating the
cellular mechanisms linking Lp(a) and OxPL with
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mild to moderate AS, elevated Lp(a) and
OxPL on apolipoprotein B-100 (apoB) were
associated with higher rates of disease pro-
gression determined by echocardiography, as
well as an increased need for AVR (11). How-
ever, this ﬁnding has not been validated in
the elderly patients encountered in routine
clinical practice nor in patients with more
advanced aortic stenosis. Moreover, the
relationship of Lp(a) and OxPL to sensitive
measures of aortic valve calciﬁcation such as
computed tomography (CT) calcium scoring
or 18F-sodium ﬂuoride (NaF) positron emis-
sion tomography (PET) (a marker of calciﬁ-
cation activity) has not been evaluated.
In this study, we analyzed a clinically
representative cohort of patients with AS and
compared baseline Lp(a) and OxPL-apoB levels to
calciﬁcation activity in the aortic valve using 18F-NaF
PET; to future AS progression, as assessed both by
echocardiography and CT calcium scoring; and to
future clinical events. In parallel, we performed
mechanistic in vitro experiments to investigate the
effects of Lp(a) and OxPL on valvular interstitial cell
(VIC) calciﬁcation and whether these effects may be
counteracted.
METHODS
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FIGURE 1 Study Diagram
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Study diagram of the study cohorts, describing the number of patients from the Ring of Fire and SALTIRE trials undergoing the different forms
of baseline and repeat imaging. 18F-NaF PET ¼ ﬂuorine-18 sodium ﬂuoride positron emission tomography; CT ¼ computed tomography;
Lp(a) ¼ lipoprotein(a); OxPL-apoB ¼ oxidized phospholipids on apolipoprotein B-100; SALTIRE ¼ Scottish Aortic Stenosis and Lipid Lowering
Trial, Impact on Regression.
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2152Regression) (13) (Figure 1). Both studies were con-
ducted with local research ethics committee approval
and with the written informed consent of all
participants.
In the Ring of Fire study, patients age >50 years
and matched control subjects were recruited from the
outpatient department of the Edinburgh Heart
Centre. PET, CT calcium scoring, and echocardiogra-
phy were performed to assess disease activity and
progression in a total of 81 patients. Patients were
prospectively followed at the outpatient clinic for
adverse clinical outcomes. For the present study, we
included all AS patients who had baseline samples
available for Lp(a) and OxPL measurements, as well
as available progression data: 80 of 81 (98.8%)
patients.
SALTIRE was a prospective trial assessing the ef-
fect of high-dose statin on AS progression. Patients
with calciﬁc AS, deﬁned as a peak aortic jet velocity
>2.5 m/s and aortic valve calciﬁcation on echocardi-
ography, were eligible for inclusion. The main
exclusion criteria were pre-existing statin therapy,
planned aortic valve replacement, and moderate or
severe left ventricular systolic impairment. Echocar-
diography was performed at baseline, at each annual
visit, and before withdrawal from the trial. For the
present study, all patients who had baseline Lp(a)and OxPL-apoB measurements and available echo-
cardiographic progression data were included: 65 of
155 (41.9%) patients. These patients had similar
baseline characteristics compared with the subjects in
whom baseline Lp(a) and OxPL measurements were
not available (Online Table 1).
LP(A), OxPL AND AUTOTAXIN MEASUREMENTS.
Plasma Lp(a) and OxPL-apoB were measured in all
patients in both cohorts using chemiluminescent
immunoassays, as previously described (11). Auto-
taxin (ATX) associated with Lp(a) and apoB was also
measured (5).
BASELINE CALCIFICATION ACTIVITY WITH 18F-NaF
PET. 18F-NaF PET provides a measure of valvular
calciﬁcation activity in aortic stenosis, binding pref-
erentially to developing tissue microcalciﬁcation and
predicting AS progression (12,14–17). In this study,
aortic valve calciﬁcation activity was assessed at
baseline in the Ring of Fire cohort using 18F-NaF
PET/CT on a hybrid scanner (Biograph mCT, Siemens
Medical Systems, Erlangen, Germany) 60 min after
administration of 125 MBq of 18F-NaF.
PET data were reconstructed with the use of
the Siemens Ultra-HD reconstruction algorithm. Cor-
rections were applied for attenuation, dead time,
scatter and random coincidences. Image analysis was
FIGURE 2 Baseline Lp(a) and OxPL-apoB Levels in Our Cohort and Association With Baseline Aortic Valve CT Calcium Score and Peak
Aortic Valve Jet Velocity on Echocardiography
p = 0.429 p = 0.355
Ca
-S
co
re
 (A
U)
C
6000
2000
4000
0
8000
≤35 mg/dL
Lp(a) tertile 1 & 2
>35 mg/dL
Lp(a) tertile 3
AV
 C
a-
Sc
or
e 
(A
U)
D
6000
2000
4000
0
8000
≤2.8 nM
OxPL-apoB
tertile 1 & 2
>2.8 nM
OxPL-apoB
tertile 3
Lp
(a
) m
g/
dL
AS Patients
Tertile 3
(35 mg/dL)
A
100
50
0
150
Ox
PL
-a
po
B 
(n
M
)
AS Patients
Tertile 3
(2.80 nM)
B
10
5
0
15
p = 0.150 p = 0.216
≤35 mg/dL
Lp(a) tertile 1 & 2
>35 mg/dL
Lp(a) tertile 3
E
4
2
0
6
V m
ax
 (m
/s
)
≤2.8 nM
OxPL-apoB
tertile 1 & 2
>2.8 nM
OxPL-apoB
tertile 3
F
4
2
0
6
V m
ax
 (m
/s
)
(A) Lp(a) and (B) OxPL-apoB distribution in 145 patients. Baseline aortic valve CT calcium scores for the top versus combined middle and
bottom tertiles of (C) Lp(a) and (D) OxPL-apoB. Baseline peak aortic jet velocity for the top versus combined middle and bottom tertiles of
(E) Lp(a) and (F) OxPL-apoB. Abbreviations as in Figure 1.
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2153performed on fused PET/CT datasets on a dedicated
workstation (Osirix version 3.5.1. 64-bit, Osirix Im-
aging Software, Geneva, Switzerland). As previously
reported, regions of interest were drawn around the
aortic valve on reoriented coaxial PET/CT slices in theplane of the aortic valve, generating standard
uptake values (SUV) (17). In a most diseased segment
(MDS) approach, the 2 contiguous valve slices
with the highest SUV values were averaged to
generate the SUVMDS. These SUV values were
TABLE 1 Baseline Characteristics of Patients
All Patients
(N ¼ 145)
Lp(a) Levels
p Value
Tertiles 1 and 2 Tertile 3
#35 mg/dl
(n ¼ 96)
>35 mg/dl
(n ¼ 49)
Clinical parameters
Age, yrs 70.3  9.9 69.5  9.8 72.0  10.0 0.14
Male 99 (68.3) 67 (69.8) 32 (65.3) 0.58
Body mass index, kg/m2 27.6  4.3 27.6  4.3 27.6  4.5 0.94
Ischemic heart disease 37 (26.2) 22 (22.9) 15 (30.6) 0.31
Cardiovascular disease 53 (36.6) 32 (33.3) 21 (42.9) 0.26
Smoking (active or former) 92 (63.4) 60 (62.5) 32 (66.7) 0.62
Diabetes mellitus 15 (10.3) 8 (8.4) 8 (16.3) 0.15
Hypertension 83 (57.2) 55 (57.3) 28 (58.3) 0.91
Laboratory data
Creatinine, mg/dl 91.8  24.7 91.7  22.6 92.1  28.7 0.92
Urea, mg/dl 6.9  2.5 6.74  2.04 7.26  3.18 0.24
Calcium, mg/dl 2.3  0.1 2.32  0.10 2.34  0.18 0.27
Alkaline phosphatase, U/l 84.4  41.2 83.3  23.2 86.4  62.9 0.74
Total cholesterol, mg/dl 206  49 206  50 207  47 0.98
LDL cholesterol, mg/dl 111  43 117  43 100  42 0.02
HDL cholesterol, mg/dl 56  17 55  17 58  16 0.32
Triglycerides, mg/dl 133 (97–195) 137 (97–195) 133 (93–173) 0.53
Lipoprotein(a), mg/dl 15.2 (6.6–52.2) 9.5 (3.9–15.2) 61.1 (51.6–79.4) —
OxPL-apoB, nmol/l 1.8 (1.2–4.8) 1.3 (0.9–1.8) 5.8 (4.7–9.0) <0.001
Medication
Statin at baseline 47 (32.4) 26 (27.1) 21 (42.9) 0.06
Statin during follow-up 82 (56.6) 50 (52.1) 32 (65.3) 0.13
ACE inhibitor 43 (29.7) 26 (27.1) 17 (34.4) 0.30
Echocardiography
Peak aortic jet velocity, m/s 3.42  0.79 3.36  0.74 3.56  0.89 0.15
Peak aortic valve gradient, mm Hg 48.9  23.4 46.4  20.5 53.8  27.9 0.11
Mean aortic valve gradient, mm Hg 26.7  14.2 25.5  12.7 29.2  16.6 0.14
Aortic valve area, cm2 1.07  0.40 1.10  0.42 1.02  0.36 0.30
Values are mean  SD, n (%), or median (interquartile range). LDL cholesterol was corrected for cholesterol
content in Lp(a): LDL-C ¼ LDL-C  Lp(a) mass  0.3.
ACE ¼ angiotensin-converting enzyme; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein;
Lp(a) ¼ lipoprotein (a); OxPL-apoB ¼ oxidized phospholipids on apolipoprotein B-100.
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2154corrected for blood-pool activity measured in the
right atrium to generate tissue-to-background-ratio
values (TBRMDSmean) (17).
PROGRESSION IN CT CALCIUM SCORES. Progression
in the aortic valve CT calcium score was assessed in
patients from the Ring of Fire study. An ECG-gated
breath-hold CT scan (noncontrast-enhanced, 40 mA/rot,
100 kV) was performed at baseline for calculation of
the aortic valve calcium score on a hybrid PET/CT
scanner (Biograph mCT). Repeat CT calcium scores
were performed on the same scanner using the
same protocol, and annualized change in CT calcium
score calculated for each patient as previously re-
ported (14). CT scans acquired in the SALTIRE trial
were performed using an older scanner without ECG-
gating and were therefore not deemed suitable for
analysis.HEMODYNAMIC PROGRESSION ON ECHOCARDIOGRAPHY.
All 145 patients from both cohorts underwent
assessment of hemodynamic AS severity and disease
progression by the same research ultrasonographer
(A.W.) on a dedicated echocardiography machine
following a standardized protocol and according to
2006 American Heart Association/American College
of Cardiology criteria (Online Appendix) (12,13). Pro-
gression in AS disease severity was assessed by
calculating the annualized change in peak trans-
valvular aortic valve velocity, using the ﬁnal echo-
cardiography data available collected at 1, 2, or 3 years
after baseline assessments.
CLINICAL OUTCOMES. Clinical outcomes were
collected prospectively across both patient cohorts
and adjudicated by 2 independent and blinded in-
vestigators. The primary clinical endpoint was a
composite of AVR and death, and the secondary
endpoint was a composite of AVR and cardiovascular
death. AVR was collected from individual electronic
patient records. Deaths and cause of death were
captured in the General Register of Scotland. All
deaths were conﬁrmed by independent review of
each patient’s electronic health care record where
available.
EXPERIMENTAL METHODS. Expanded experimental
methods and materials are presented in the Online
Appendix. In brief, human VICs from control non-
mineralized aortic valves were isolated and treated
with TGF-b (positive control), Lp(a) isolated from
healthy subjects (with or without monoclonal anti-
body E06), or recombinant apolipoprotein(a) con-
structs 17K-WT and 17KDLBS10.
STATISTICAL ANALYSIS. This study is a post hoc
analysis of 2 pooled cohorts in whom samples were
available for Lp(a) and OxPL-apoB measurements; no
formal sample size evaluations were therefore per-
formed. However, post hoc power analyses were
performed using nQuery Advisor version 7.0 (Statis-
tical Solutions, Cork, Ireland) and are reported in the
Online Appendix. Data are presented as mean  SD
for continuous variables with normal distribution,
medians with interquartile ranges for continuous
variables with non-normal distribution, and number
(percentage) for categorical variables. Normality was
assessed by inspection of histograms and the Shapiro-
Wilk test. To assess differences in continuous data
across Lp(a) and OxPL tertiles (top tertile vs. com-
bined middle and bottom tertiles), an unpaired Stu-
dent’s t-test or Mann-Whitney U test was performed,
as appropriate. To assess differences in categorical
data across Lp(a) and OxPL tertiles, a chi-square test
was performed. In multiple regression analysis,
FIGURE 3 Baseline Calciﬁcation Activity and Aortic Stenosis Progression According to Patient Lp(a) and OxPL-apoB Levels
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At baseline, patients in the top Lp(a) and OxPL-apoB tertiles have increased valvular 18F-NaF uptake, as a marker of calciﬁcation activity, compared with the combined
middle and bottom tertiles (A and B). (C) Two examples of increased valvular 18F-NaF PET uptake at baseline (left), which predicted progression to macrocalciﬁcation
on CT after 2 years (right) (16). Patients in the top Lp(a) and OxPL-apoB tertiles also demonstrated faster progression in aortic valve CT calcium score (D and E), and
faster hemodynamic progression, expressed as the annualized change in peak aortic jet velocity (DVmax) (F and G). Abbreviations as in Figure 1.
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2155dependent variables were 18F-NaF uptake, aortic
valve calcium score, and progression of peak aortic jet
velocity. Independent variables included the baseline
peak aortic jet velocity, baseline aortic valve calcium
score, Lp(a) and OxPL-apoB tertiles, and thetraditional cardiovascular risk factor variables (age,
sex, body mass index, history of cardiovascular dis-
ease, smoking status, diabetes mellitus, hyperten-
sion, and plasma creatinine). Following sensitivity
analyses, baseline low-density lipoprotein cholesterol
TABLE 2 Multiple Linear Regression Analysis
18F-NaF PET Activity: TBRMDSmean
Progression in AV Calcium Score: DCa-Score
(100 AU/yr)
Change in Peak Aortic
Jet Velocity: Vmax, m/s/yr
Unst. b (95% CI) Std. b p Value Unst. b (95% CI) Std. b p Value Unst. b (95% CI) Std. b p Value
Age, per 10 yrs 0.100
(0.019 to 0.218)
0.192 0.098 0.253
(1.016 to 0.511)
0.082 0.507 0.006
(0.034 to 0.046)
0.029 0.771
Male 0.160
(0.087 to 0.408)
0.189 0.200 1.030
(0.488 to 2.547)
0.225 0.178 0.033
(0.123 to 0.058)
0.073 0.477
Body mass index, kg/m2 0.018
(0.005 to 0.041)
0.179 0.126 0.126
(0.324 to 0.072)
0.186 0.204 0.004
(0.005 to 0.014)
0.092 0.349
Cardiovascular disease 0.002
(0.216 to 0.212)
0.002 0.986 0.102
(1.107 to 1.310)
0.023 0.866 0.029
(0.057 to 0.114)
0.068 0.508
Smoking 0.069
(0.231 to 0.093)
0.085 0.395 0.559
(1.505 to 0.386)
0.128 0.238 0.017
(0.097 to 0.062)
0.041 0.666
Diabetes mellitus 0.164
(0.422 to 0.094)
0.151 0.208 0.056
(1.662 to 1.774)
0.010 0.948 0.086
(0.222 to 0.050)
0.124 0.214
Hypertension 0.048
(0.145 to 0.241)
0.054 0.621 0.406
(1.561 to 0.749)
0.084 0.481 0.027
(0.106 to 0.053)
0.065 0.506
Creatinine, per 10 mg/dl 0.004
(0.026 to 0.034)
0.026 0.811 0.201
(0.410 to 0.008)
0.256 0.059 0.001
(0.018 to 0.015)
0.016 0.874
Lipoprotein(a) top tertile 0.262
(0.095 to 0.410)
0.307 0.002 1.453
(0.515 to 2.391)
0.328 0.003 0.086
(0.007 to 0.166)
0.197 0.034
Baseline AV Ca-score, per 100 AU 0.012
(0.007 to 0.018)
0.529 <0.001 0.109
(0.071 to 0.147)
0.670 <0.001 — — —
Baseline Vmax, m/s — — — — — — 0.040
(0.012 to 0.093)
0.144 0.130
AV Ca-score ¼ aortic valve calcium score; CI ¼ conﬁdence interval; Std. b ¼ standardized beta coefﬁcient; TBRMDSmean ¼ tissue-to-background ratio of the most diseased segment; Unst. b ¼ unstandardized
beta coefﬁcient; Vmax ¼ peak aortic jet velocity.
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(Online Table 2). Kaplan-Meier curves of time-to-
event data were compared with the use of the log-
rank test. Cox proportional hazards models were
used to calculate hazard ratios by Lp(a) and OxPL-
apoB tertiles. Unpaired Student’s t-tests were used
to deﬁne differences between experimental condi-
tions. Statistical analyses were performed using the
SPSS statistics software version 24 (IBM, Armonk,
New York). A p value <0.05 was considered statisti-
cally signiﬁcant.
RESULTS
STUDY COHORT AND BASELINE CHARACTERISTICS.
After combining available data from the Ring of Fire
cohort and the SALTIRE trial, a total of 145 elderly
patients had samples available for Lp(a) and OxPL-
apoB measurements (Figures 2A and 2B). In both
studies, disease severity assessed by echocardiogra-
phy was comparable (Online Table 3). The average age
was 70.3  9.9 years, and patients had a high preva-
lence of comorbidity. Baseline characteristics for the
combined cohort are listed in Table 1, according to the
top Lp(a) tertile (>35 mg/dl) versus combined middle
and bottom tertiles (Lp(a) #35 mg/dl). Patients in the
top Lp(a) tertile were well balanced compared with
the lower tertiles with respect to baseline clinical
characteristics, CT aortic valve calcium scores, andechocardiographic measures (Figures 2C and 2E).
Similarly, baseline clinical and imaging characteris-
tics were well balanced between patients in the top
(>2.8 nmol/l) versus lower OxPL-apoB tertiles
(#2.8 nmol/l) (Figures 2D and 2F and Online Table 4).
INCREASED VALVULAR CALCIFICATION ACTIVITY
IN PATIENTS WITH ELEVATED LP(A) AND OxPL-apoB. To
investigate calciﬁcation activity in the aortic valve,
18F-NaF PET/CT was performed in 80 patients from
the Ring of Fire cohort (age 72.4  8.4 years; 67%
men). Patients in the top Lp(a) tertile demonstrated
increased aortic valve 18F-NaF PET activity compared
with patients in the lower Lp(a) tertiles (TBRMDSmean:
2.16 vs. 1.97; p ¼ 0.043) (Figure 3A). Similarly,
increased valvular 18F-NaF activity was observed in
the top versus the lower OxPL-apoB tertiles
(TBRMDSmean: 2.15 vs. 1.98; p ¼ 0.047) (Figure 3B).
After adjustment for baseline calcium score and
traditional cardiovascular risk factors, the top Lp(a)
tertile was an independent predictor of 18F-NaF up-
take (ß: 0.262 [95% CI: 0.095 to 0.410]; p ¼ 0.002) as
was the top OxPL-apoB tertile (ß: 0.204 [95% CI: 0.040
to 0.367]; p ¼ 0.016) (Table 2, Online Table 5).
FASTER PROGRESSION OF CT CALCIUM SCORES IN
PATIENTS WITH ELEVATED LP(A) AND OxPL-apoB.
Whether this increased calciﬁcation activity trans-
lated into faster progression of aortic valve calcium
burden was subsequently assessed using repeat CT
FIGURE 4 Aortic Valve Replacement or Death During Follow-Up According to Patient’s Lp(a) and OxPL-apoB Levels
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Kaplan-Meier curves show the composite endpoint of aortic valve replacement surgery and death. Patients in the top Lp(a) and OxPL-apoB tertiles had more events
than those in the lower tertiles (A and B). Multivariate Cox proportional hazards analysis for aortic valve replacement surgery and death. Lp(a) and OxPL-apoB emerged
as an independent predictor of events alongside the baseline peak aortic jet velocity (C and D). Hazard ratio for age is per 10 years, BMI per kg/m2, creatinine per
10 mg/dl; Vmax per m/s. BMI ¼ body mass index; CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease; Vmax ¼ peak aortic jet velocity; other abbreviations as in
Figure 1.
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2157calcium scoring scans. A total of 51 patients under-
went repeat CT calcium scoring at 2 years (age 72.6 
7.1 years; 66% men): the median progression in aortic
valve calcium score was 3 faster for the top tertile of
Lp(a) compared with the lower tertiles (309 AU/year
[interquartile range: 142 to 483 AU/year] vs. 93 AU/
year [interquartile range: 56 to 296 AU/year];
p ¼ 0.015) (Figure 3D). Similarly, progression in aortic
valve calcium score for the top OxPL-apoB tertile was
3 faster than in the lower tertiles (297 AU/year
[interquartile range: 139 to 489 AU/year vs. 96 AU/
year [interquartile range: 57 to 333 AU/year];
p ¼ 0.024) (Figure 3E).
After adjustment for baseline calcium score and
traditional cardiovascular risk factors, the top Lp(a)
tertile was an independent predictor of annualizedprogression in the aortic valve calcium score (ß: 144
AU/year [95% CI: 52 to 239 AU/year]; p ¼ 0.003)
(Table 2). Similar results were observed for the top
OxPL-apoB tertile, after the same multivariable
adjustment (ß: 137 AU/year [95% CI: 43 to 230 AU/
year]; p ¼ 0.005) (Online Table 5).
FASTER HEMODYNAMIC PROGRESSION IN PATIENTS
WITH ELEVATED LP(A) AND OxPL-apoB. In total,
repeat echocardiography was performed in 129 pa-
tients (89%), with ﬁnal echocardiography data
collected at 1 year in 11 (7.6%) patients, 2 years in
82 (56.6%) patients and 3 years in 36 (24.8%) pa-
tients. Annualized progression in hemodynamic AS
severity as measured by the peak aortic jet velocity
was almost double in the top versus the lower Lp(a)
FIGURE 5 Lp(a) Induces Osteogenic Differentiation in VICs
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(A to C) VICs in osteogenic media only conditions were used as the baseline comparator, while addition of TGF-b served as a positive
calciﬁcation control. One week of exposure to Lp(a) (100 mg/dl) induced gene expression of the inﬂammatory mediator IL-6 and osteoblastic
regulators BMP2 and RUNX2. Pre-incubation with the E06 antibody targeting OxPL reduced the transcriptional effect of Lp(a), suggesting that
OxPL is intrinsic to the pro-calciﬁc effects of Lp(a). The role of OxPL was further validated using 2 r-apo(a) constructs that differ in their
lysine binding sites and consequently their capacity to bind OxPL. (D to F) Three days of exposure to r-apo(a) 17K-WT construct induced
increased expression of osteogenic genes. This effect was reduced with the 17KDLBS10 construct that lacks the ability to bind OxPL.
(G and H) Bright-ﬁeld microscopy images of VICs after stimulation with 17K constructs. 17K-WT induces an activated, rhomboid shape,
whereas 17KDLBS10 was characterized by a quiescent, spindle-shaped morphology. Data represent mean  SEM for at least n ¼ 3
independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 compared with OSM only or comparison between 17K-WT and 17KDLBS10.
17K-WT ¼ 17 kringles wild-type r-apo(a) construct; 17KDLBS ¼ 17K r-apo(a) construct without lysine binding site; BMP2 ¼ bone morpho-
genetic protein 2; E06 ¼ E06 monoclonal antibody; IL-6 ¼ interleukin-6; OSM ¼ osteogenic medium; RUNX2 ¼ Runt-related transcription
factor 2; TGF-b ¼ transforming growth factor beta. VIC ¼ valvular interstitial cell.
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2159tertiles (0.23  0.20 m/s/year vs. 0.14  0.20 m/s/
year; p ¼ 0.019) (Figure 3F). Similar results were
observed when comparing progression in the top
versus lower OxPL-apoB tertiles (0.23  0.21 m/s/
year vs. 0.15  0.20 m/s/year; p ¼ 0.054)
(Figure 3G).
In multiple regression analysis, the top Lp(a) tertile
(ß: 0.086 m/s/year [95% CI: 0.007 to 0.166 m/s/year];
p ¼ 0.034) was an independent predictor of progres-
sion in peak aortic jet velocity after adjusting for
baseline peak aortic jet velocity and traditional car-
diovascular risk factors (Table 2). Again, results were
similar with respect to the top OxPL-apoB tertile (ß:
0.041 m/s/year [95% CI: 0.011 to 0.093 m/s/year];
p ¼ 0.054) (Online Table 5).
HIGHER EVENT RATES IN PATIENTS WITH
ELEVATED LP(A) AND OxPL-apoB. After a median of
5 years follow-up (interquartile range: 2.7 to 5 years),
43 patients had undergone AVR and 22 patients had
died, including 6 cardiovascular deaths and 3 pa-
tients who had AVR as their ﬁrst event. The primary
composite outcome of AVR or all-cause mortality
occurred in 29 (59.2%) patients in the top tertile of
Lp(a) and in 33 (34.4%) patients in the lower Lp(a)
tertiles group (hazard ratio [HR] for Lp(a) top tertile:
1.87; 95% conﬁdence interval [CI]: 1.13 to 3.08;
p ¼ 0.014) (Figure 4A). The primary composite
endpoint occurred in 28 (58.3%) patients in the top
OxPL-apoB tertile and 34 (35.1%) patients in the
lower OxPL-apoB tertiles group (HR for OxPL-apoB
top tertile: 1.83; 95% CI: 1.11 to 3.02; p ¼ 0.028)
(Figure 4B).
The secondary composite outcome of AVR or car-
diovascular death occurred in 24 (49.0%) patients in
the top tertile of Lp(a) and in 29 (30.2%) in the lower
Lp(a) tertiles group (HR for Lp(a) top tertile: 1.72; 95%
CI: 1.00 to 2.95; p ¼ 0.050) (Online Figure 1A). The
secondary composite endpoint occurred in 23 (47.9%)
patients in the top tertile of OxPL-apoB and in 30
(30.9%) patients in the lower OxPL-apoB tertiles
group (HR for top OxPL-apoB tertile: 1.68; 95% CI:
0.97 to 2.89; p ¼ 0.063) (Online Figure 1B).
Adjustment for baseline peak aortic jet velocity
and traditional cardiovascular risk factors did not
markedly change the association of the primary
composite endpoint, with both the top tertile of
Lp(a) (adjusted HR: 1.74; 95% CI: 1.02 to 2.98;
p ¼ 0.044) (Figure 4C) and the top tertile of OxPL-
apoB (adjusted HR: 1.69; 95% CI: 1.00 to 2.87;
p ¼ 0.050) (Figure 4D) emerging as independent
predictors. Multivariable analyses for the secondary
composite endpoint demonstrated comparable re-
sults (Online Figures 1C and D).STRATIFICATION BY ATX REVEALS DIFFERENCES IN
HEMODYNAMIC PROGRESSION. Complete results are
presented in Online Table 6 and Online Figures 2 and 3.
Patients with above-median levels of ATX-Lp(a) (0.20
 0.19 m/s/year vs. 0.09  0.19 m/s/year; p ¼ 0.012)
and below median levels of ATX-apoB 0.10  0.17 m/s/
year vs. 0.19  0.21 m/s/year; p ¼ 0.028) had faster
hemodynamic progression, but only in the lower ter-
tiles of Lp(a) and OxPL-apoB, respectively (n ¼ 87 in
lower tertiles). There were no associations between
ATX-Lp(a) or ATX-apoB and 18F-NaF uptake, progres-
sion in CT calcium score, or the composite outcome of
AVR and death.
LP(A) INDUCES OSTEOGENIC DIFFERENTIATION OF
VICs THROUGH ITS OxPL CONTENT. To understand
the mechanism by which Lp(a) might induce aortic
valve calciﬁcation, we aimed to study the effect of
Lp(a) on VICs. As a positive control for osteogenic
differentiation of VICs, we used TGF-b, an estab-
lished mediator of calciﬁcation of VICs in culture (18).
First, we isolated Lp(a) from serum of healthy
human subjects with elevated Lp(a) levels. After
1 week of exposure to Lp(a) 100 mg/dl, we evaluated
osteogenic differentiation of VICs by assessing gene
expression of the key inﬂammatory mediator IL-6
and the major osteoblastic transcription factors BMP2
and RUNX2. Lp(a) increased IL-6 expression 2.1-fold
(p ¼ 0.009), BMP2 expression 3.2-fold (p ¼ 0.048)
and RUNX2 expression 2.2-fold (p ¼ 0.020),
compared with osteogenic medium only. Impor-
tantly, pre-incubation of Lp(a) with the E06 mono-
clonal antibody against OxPL markedly attenuated
these Lp(a)-mediated osteogenic differentiation ef-
fects (Figures 5A to 5C).
Next, we addressed the role of the OxPL moiety
on Lp(a) using 2 different r-apo(a) constructs,
consisting of 17 kringles (17K) with different lysine
binding sites (LBS) that affect their ability to bind
OxPL covalently. The r-apo(a) 17K-WT construct
contains an intact and functional LBS, while
17KDLBS10 contains a mutation in the LBS that
renders it defective in binding OxPL. Similar to Lp(a),
the 17K-WT construct induced IL-6, BMP-2, and
RUNX2 expression. These transcriptional effects
diminished with 17KDLBS10, again supporting an
important role for OxPL in mediating Lp(a)-induced
VIC calciﬁcation (Figures 5D to 5F). In addition,
when assessing cell morphology, 17K-WT induced an
activated rhomboid shape, suggesting VIC activation
or phenotype transformation. In contrast, VICs
exposed to 17KDLBS10 demonstrated a spindle-
shaped morphology, corresponding to a quiescent
state (Figures 5G and 5H).
CENTRAL ILLUSTRATION Lp(a) and OxPL Drive Disease Progression by Aggravating Calciﬁcation in
Aortic Stenosis Patients
Zheng, K.H. et al. J Am Coll Cardiol. 2019;73(17):2150–62.
Aortic stenosis patients with elevated levels of Lp(a) and OxPL-apoB demonstrate increased calciﬁcation activity in the valve as measured by 18F-NaF PET, compared
with patients with low levels of Lp(a) and OxPL-apoB. During follow-up, this resulted in faster progression of CT calcium score and faster hemodynamic progression as
measured by echocardiography. Ultimately, these patients have an increased risk of aortic valve replacement and death. Lp(a) ¼ lipoprotein(a); OxPL-apoB ¼ oxidized
phospholipids on apolipoprotein B-100.
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In this multimodality imaging study, we present the
novel ﬁnding that increased Lp(a) and OxPL-apoB
levels in elderly patients with advanced AS are asso-
ciated with increased valvular calciﬁcation activity
using 18F-NaF PET and conﬁrmed faster rates of dis-
ease progression using both CT calcium scoring and
echocardiography (Central Illustration). This trans-
lated into an increased incidence of AVR and death.
In vitro studies demonstrated that these observations
appear to be driven by the pro-osteogenic effects of
Lp(a) on VICs, mediated through its OxPL content,
which could be alleviated with the E06 antibody that
binds to and inactivates OxPL. Collectively, these
data suggest that Lp(a) and its associated OxPL are
important therapeutic targets in AS. Clinical trials arenow warranted investigating whether novel Lp(a)
lowering compounds or therapeutic antibodies tar-
geting OxPL are effective in slowing disease pro-
gression in aortic stenosis.
This is the ﬁrst study to combine PET, CT, and
echocardiography data to investigate the association
among elevated Lp(a), OxPL, valve calciﬁcation ac-
tivity, and disease progression in patients with AS. In
patients with comparable disease severity at baseline,
we demonstrate that elevated Lp(a) as well as OxPL-
apoB levels are independently associated with
increased valvular 18F-NaF uptake: a validated mea-
sure of active tissue calciﬁcation predicting AS pro-
gression (14). Indeed, this effect was reproduced
when examining aortic stenosis progression directly,
with elevated Lp(a) and OxPL-apoB independently
associating with faster hemodynamic progression on
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2161echocardiography, faster progression in the aortic
valve calcium score on CT, as well as an increased
clinical event rate.
Our data support a post hoc analysis of the
ASTRONOMER (Aortic Stenosis Progression Observa-
tion: Measuring Effects of Rosuvastatin) trial (11), in
which patients with mild to moderate AS and
elevated Lp(a) (top tertile >58.5 mg/dl) or OxPL-apoB
levels were reported to have faster AS progression.
However, the ASTRONOMER trial only examined
echocardiographic progression. Furthermore, the pa-
tient population was considerably younger than that
encountered in routine clinical practice (mean age 57
years), and nearly one-half of patients had a bicuspid
valve. This led many to question the relevance of
Lp(a) as a therapeutic target in the majority of elderly
patients seen clinically with AS. Here, we ﬁnd that in
a study population with a mean age of 70 years,
elevated Lp(a) (using a cut-off of 35 mg/dl) and OxPL-
apoB (>2.8 nmol/l) were associated with a 2- to 3-fold
faster rate of disease progression measured by echo-
cardiography and CT calcium scoring. Our data
therefore extend the generalizability of Lp(a) and its
associated OxPL as independent risk factors driving
AS progression to the wider clinical population and
suggest that patients with elevated Lp(a) and OxPL-
apoB levels might beneﬁt from a reduction in these
levels to slow disease progression.
What is the mechanism for these observations? Our
in vitro data conﬁrm that Lp(a) increases expression
of key osteogenic genes in human VICs, committing
them to an osteoblastic-like cell type (19). Using the
monoclonal antibody E06, we demonstrate that
blocking the OxPL moiety carried by Lp(a) diminishes
the osteogenic response of VICs to Lp(a). Moreover,
we substantiated the key role of OxPL in eliciting this
pro-osteogenic response using r-apo(a) constructs
with or without the capacity to bind OxPL. Together,
these data support emerging published data that
suggest an important role for the OxPL content of
Lp(a) in valve calciﬁcation (5,20,21). They also suggest
that novel therapies targeting OxPL may be useful in
slowing aortic valvular calciﬁcation, as well as
atherosclerosis, as recently demonstrated using a
hypercholesterolemic mouse model expressing a
single-chain variable fragment of E06 (22).
CLINICAL IMPLICATIONS. In the absence of any
successful drug intervention able to reduce AS pro-
gression, it is instrumental to identify key factors
contributing to this disease process. In line with
epidemiological surveys and Mendelian randomiza-
tion studies establishing the association of Lp(a) and
OxPL with AS incidence (4), we have now conﬁrmed
that elevated Lp(a) and OxPL-apoB levels areassociated with increased valve calciﬁcation activity
and faster disease progression in a clinically repre-
sentative cohort of AS patients. In view of the high
prevalence of elevated Lp(a) levels in the general
population (>50 mg/dl in up to 20%) (23), therapies
aimed at lowering Lp(a) may have signiﬁcant effect,
particularly as they might also have beneﬁcial effects
on coexistent atherosclerotic disease. Alternatively,
therapies seeking to inhibit valvular calciﬁcation may
theoretically adversely affect any plaque-stabilizing
effects of calciﬁcation in regions of atheroma.
Although to our knowledge, no clinical data exist to
support this hypothesis, future studies targeting
calciﬁcation will need to be vigilant regarding their
effects on atherosclerosis. Emerging therapies such as
antisense oligonucleotides have shown that
decreasing circulating Lp(a) levels by up to 95% is
feasible with a favorable safety and tolerability proﬁle
(9). Randomized controlled trials will be needed to
test the hypothesis that lowering Lp(a) or OxPL in
patients with elevated levels truly slows down AS
progression rates and ultimately improves clinical
outcomes. Traditionally, such studies have concen-
trated on the effects of drugs on hemodynamic pro-
gression assessed by echocardiography. However,
increasingly they are also examining progression in
the CT calcium score and changes in the 18F-NaF PET
signal (SALTIRE-2 [Study Investigating the Effect of
Drugs Used to Treat Osteoporosis on the Progression
of Calciﬁc Aortic Stenosis], NCT02132026; BASIK2
[Bicuspid Aortic Valve Stenosis and the Effect of
vItamin K2 on Calciummetabolism on 18F-NaF PET/
MRI], NCT02917525), as used in the present study.
STUDY LIMITATIONS. We have pooled 2 prospective
studies to increase power, but the number of patients
per tertile remains relatively modest, conferring the
risk of false positive ﬁndings. The Agatston method to
quantify valvular calciﬁcation has inherent limita-
tions that potentially decrease its accuracy in
detecting disease progression (24). However, other
methods for measuring valve calcium burden using
CT remain relatively unexplored. Furthermore, there
were differences in statin use across the cohorts,
although randomized controlled trials and a recent
meta-analysis demonstrated that statins do not
impact hemodynamic disease progression or reduce
valve-related events in AS (2). Finally, future studies
with larger sample sizes are needed to improve our
understanding of the Lp(a)-OxPL-ATX pathway in AS.
CONCLUSIONS
In aortic stenosis, patients with elevated Lp(a) and
OxPL-apoB plasma levels demonstrate increased
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Elevated blood levels of Lp(a) and OxPL-apoB are
associated with accelerated valve calciﬁcation and
hemodynamic progression of aortic stenosis.
TRANSLATIONAL OUTLOOK: Randomized trials
are required to establish whether lowering Lp(a)
and/or inhibiting OxPL can slow progression of clinical
aortic stenosis.
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gression assessed both by echocardiography and CT,
and an increased risk of AVR or death than subjects
with lower levels. In vitro studies show that this
effect appears to be mediated by the pro-osteogenic
effects of Lp(a) and OxPL on valvular interstitial
cells, and that these effects are potentially revers-
ible with targeted treatment inactivating OxPL.
These ﬁndings provide a rationale for clinical
studies aiming to reduce elevated Lp(a) and OxPL
levels in patients with aortic stenosis as a means of
slowing disease progression and delaying the need
for AVR.
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